|
|
|
| Vasodilator-Stimulated Phosphoprotein Alleviates Cardiomyocyte Damage in Septic Mice |
| ZHANG Jilong, SHAN Ping, HAN Yang, et al |
| The First Hospital of Wuhan, Hubei Wuhan 430022, China |
|
|
|
|
Abstract Objective: Validation of dibutyryl cyclic adenosine (Bucladesine)-mediated changes in vasodilator-stimulated phosphoprotein (VASP) in relation to cardiomyocyte action in septic mice. Methods: A mouse model of sepsis was constructed by cecum ligation perforation, and the experiment was divided into: control (Con), sham-operated (Sham), model (Mod) and Bucladesine (Buc) groups. Biochemical assays were performed to detect tissue malondialdehyde (MDA) and superoxide dismutase (SOD) levels in serum and myocardium. Flow cytometry was performed to detect reactive oxygen species (ROS) levels in myocardial tissue and mitochondrial membrane potential in cells. TUNEL staining was performed to detect myocardial tissue apoptosis. Hematoxylin-eosin (HE) staining was performed to observe myocardial lesions. p-VASP expression levels in myocardial tissues were measured by Western blot. Results: Compared with the control and sham groups, the model group showed significantly higher MDA levels (P<0.05), lower SOD levels (P<0.05), higher ROS levels (P<0.05), higher p-VASP and VASP protein expression levels (P<0.05) in serum and myocardial tissue, myocardial fiber breakage, laxity, increased gap, and increased TUNEL brown area coloring. Compared with the model group, the serum and myocardial tissue in the Buc group showed significantly lower MDA content (P<0.05), higher SOD content (P<0.05), lower ROS content (P<0.05), lower p-VASP and VASP protein expression levels (P<0.05), tighter myocardial fibers, and reduced TUNEL brown area coloration. Conclusion: Inhibition of p-VASP by Bucladesine can alleviate the myocardial dysfunction caused by sepsis, which mechanism of action is associated with modulation of cardiomyocyte mitochondrial activity and enhancement of cellular antioxidant capacity.
|
|
|
|
|
|
[1] Hobai IA. Mechanisms of cardiac dysfunction in sepsis[J].Shock, 2023,59(4):515-539.
[2] Zhang L, Wang YN, Ju JM, et al. Mzb1 protects against myocardial infarction injury in mice via modulating mitochondrial function and alleviating inflammation[J].Acta Pharmacol Sin,2021,42(5):691-700.
[3] Kohler D, Bibli SI, Klammer LP, et al. Phosphorylation of vasodilator-stimulated phosphoprotein contributes to myocardial ischemic preconditioning[J].Basic Res Cardiol,2018,113(2):11.
[4] Yoon SS, Kwon HW, Shin JH, et al. Anti-thrombotic effects of artesunate through regulation of cAMP and PI3K/MAPK pathway on human platelets[J].Int Mol Sci,2022,23(3):1586.
[5] Kitano T, Eguchi R, Okamatsu-Ogura Y, et al. Opposing functions of α- and β-adrenoceptors in the formation of processes by cultured astrocytes[J].Pharmacol Sci,2021,145(3):228-240.
[6] 赵琳, 邓向群, 张薇,等. 二丁酰环磷腺苷钙注射剂联合阿托伐他汀钙片治疗慢性心力衰竭患者的临床研究[J].中国临床药理学杂志,2020,36(21):3414-3417.
[7] 郝军舰, 冯智明, 才新, 等. 血必净对盲肠结扎穿孔手术诱导的脓毒症模型大鼠肺损伤的治疗作用[J].中华实验外科杂志,2019,36,(6):1141.
[8] 思飞, 甄玲玲, 王映珍, 等. 艾司洛尔对脓毒症大鼠心肌细胞凋亡影响的实验研究[J].第三军医大学学报,2020,42(13):1292-1300.
[9] Yang H, Zhang Z. Sepsis-induced myocardial dysfunction: the role of mitochondrial dysfunction[J].Inflamm Res,2021,70(4):379-387.
[10] Wang R, Xu Y, Fang Y, et al. Pathogenetic mechanisms of septic cardiomyopathy[J].Cell Physiol,2022,237(1):49-58.
[11] 赵宇含, 曹国栋, 郭立春, 等. 硫化氢通过抑制ROS介导的内质网应激改善脓毒症心肌损伤的研究[J].四川大学学报(医学版),2022,53(5):798-804.
[12] Teixeira RB, Pfeiffer M, Zhang P, et al. Reduction in mitochondrial ROS improves oxidative phosphorylation and provides resilience to coronary endothelium in non-reperfused myocardial infarction[J].Basic Res Cardiol,2023,118(1):3.
[13] Peoples JN, Saraf A, Ghazal N, et al. Mitochondrial dysfunction and oxidative stress in heart disease[J].Exp Mol Med,2019,51(12):1-13.
[14] 刘方燕, 付湘云, 罗涛, 等. 细胞自噬在脓毒症脑损伤中作用的研究进展[J].河北医学,2022,28(4):702-704. |
|
|
|
2023, Vol. 29 
